Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole:beta-cyclodextrin complex.
The purpose of this study was to achieve a better therapeutic efficacy and patient compliance in the treatment for vaginitis. Clotrimazole (1%) has been formulated in a vaginal gel using the thermosensitive polymer Pluronic F127 (20%) together with mucoadhesive polymers such as Carbopol 934 and hydroxypropylmethylcellulose (0.2% for both). To increase its aqueous solubility, clotrimazole was incorporated as its inclusion complex with 1:1 molar ratio with beta-cyclodextrin. The inclusion complex was thoroughly characterized using various techniques, including 1H NMR spectroscopy, FT IR spectrophotometry, differential scanning calorimetry, scanning electron microscopy, phase solubility studies, and determination of stability constant (k(1:1)). The gelation temperature and rheological behavior of different formulations at varying temperatures were measured. In vitro release profiles of the gels were determined in pH 5.5 citrate buffer. It was observed that complexation with cyclodextrin slowed down the release of clotrimazole considerably. Carbopol 934, on the other hand, was found to interact with beta-cyclodextrin, inducing precipitation. As far as rheological properties are concerned, thermosensitive in situ gelling was obtained with formulations containing drug:cyclodextrin complex rather than with free drug. Thus, the optimum formulation for a controlled-release thermosensitive and mucoadhesive vaginal gel was determined to be clotrimazole:beta-cyclodextrin 1% with 0.2% hydroxypropylmethylcellulose in Pluronic F127 gel (20%) providing continuous and prolonged release of active material above MIC values.
Bilensoy
Erem
E
Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, 06100 Ankara/Turkey. eremino@hacettepe.edu.tr
Rouf
M Abdur
MA
Vural
Imran
I
Sen
Murat
M
Hincal
A Atilla
AA
D000935:Antifungal Agents / Q000008:administration & dosage / Q000737:chemistry; D003022:Clotrimazole / Q000008:administration & dosage* / Q000737:chemistry*; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000032:analysis / Q000737:chemistry*; D004058:Diffusion; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D008422:Materials Testing; D009092:Mucous Membrane / Q000737:chemistry; D013696:Temperature; D014014:Tissue Adhesives / Q000008:administration & dosage / Q000032:analysis / Q000737:chemistry*; D014621:Vagina / Q000737:chemistry; D014622:Vaginal Creams, Foams, and Jellies / Q000008:administration & dosage / Q000737:chemistry*; D014627:Vaginitis / Q000188:drug therapy; D047392:beta-Cyclodextrins / Q000008:administration & dosage* / Q000737:chemistry*
D000935:Antifungal Agents; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D014014:Tissue Adhesives; D014622:Vaginal Creams, Foams, and Jellies; D047392:beta-Cyclodextrins; D003022:Clotrimazole; C031215:betadex